Immunological effectiveness of N-acetylcystein in complex therapy in severe persistent bronchial asthma patients Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008
Clinical and functional effectiveness of atorvastatin in complex therapy of severe bronchial asthma Source: Annual Congress 2009 - Asthma assessment and original therapeutic approaches Year: 2009
Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Effectiveness of prolonged cholinolytic in complex basic therapy on the tolerability of physical load in severe bronchial asthma patients Source: Annual Congress 2008 - Markers and triggers of asthma Year: 2008
Combined therapy of severe osteoporosis for patients with bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 47s Year: 2001
Advances of selenium add-on treatment in severe steroids-dependant bronchial asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010
Effects of add-on omalizumab therapy on airway wall thickening in severe persistent asthma Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
Efficacy of the long-term therapy with simbicort in children with bronchial asthma Source: Eur Respir J 2005; 26: Suppl. 49, 395s Year: 2005
Non-drug methods in complex treatment of the severe bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 513s Year: 2002
Efficacy of short-term high dose predonisolone therapy in acute exacerbation of bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 71s Year: 2001
Influence of combined antiasthmatic basic therapy on hyperinflation in patients with severe bronchial asthma Source: Eur Respir J 2007; 30: Suppl. 51, 553s Year: 2007
Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012
Bronchial asthma as neurogenic paroxysmal disease - high effectiveness of carbamazepine in asthma monotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 221s Year: 2004
Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003
Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020
Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015
Bronchial asthma as neurogenic inflammatory and paroxysmal disease – efficacy of antiepileptic drug diphenine in asthma therapy Source: Eur Respir J 2006; 28: Suppl. 50, 316s Year: 2006
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017